Prepare Yourself for Liftoff: Celyad Oncology SA (CYAD)

Celyad Oncology SA (NASDAQ: CYAD) stock jumped 6.70% on Monday to $2.07 against a previous-day closing price of $1.94. With 0.48 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.48 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2500 whereas the lowest price it dropped to was $1.8600. The 52-week range on CYAD shows that it touched its highest point at $3.99 and its lowest point at $0.46 during that stretch.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CYAD was up-trending over the past week, with a rise of 159.07%, but this was up by 97.14% over a month. Three-month performance surged to 86.49% while six-month performance rose 14.36%. The stock lost -45.24% in the past year, while it has gained 319.97% so far this year.

Float and Shares Shorts:

At present, 22.59 million CYAD shares are outstanding with a float of 22.59 million shares on hand for trading. On Dec 29, 2022, short shares totaled 0.14 million, which was 0.61% higher than short shares on Nov 29, 2022. In addition to Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME as the firm’s Co-Founder, CFO, Interim CEO & Director, Mr. David Georges serves as its VP of Fin. & Admin.

Institutional Ownership:

Through their ownership of 29.13% of CYAD’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.32% of CYAD, in contrast to 0.01% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CYAD with 0.08% of the stake, Morgan Stanley & Co. LLC holds 18,200 shares worth 18,200. A second-largest stockholder of CYAD, Citadel Securities LLC, holds 16,654 shares, controlling over 0.07% of the firm’s shares. Wells Fargo Clearing Services LLC is the third largest shareholder in CYAD, holding 12,870 shares or 0.06% stake. With a 0.01% stake in CYAD, the Fidelity Nasdaq Composite Index F is the largest stakeholder. A total of 2,012 shares are owned by the mutual fund manager. The GS Funds II – GMS US Small Cap Eq, which owns about 0.00% of CYAD stock, is the second-largest Mutual Fund holder. It holds 0 shares valued at 0.0.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2022, CYAD reported revenue of $0.00 and operating income of -$7.65M. Over the past year, revenue came in at $0.00 while operating income stood at -$25.59M. It generated -$6.48M net income for the quarter, which came to -$25.71M over the last twelve months. The EBITDA in the recently reported quarter was -$7.60M and diluted EPS was -$0.34. EBITDA for the full year was -$27.75M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CYAD since 2 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CYAD analysts setting a high price target of $11.70 and a low target of $0.53, the average target price over the next 12 months is $6.12. Based on these targets, CYAD could surge 465.22% to reach the target high and fall by -74.4% to reach the target low. Reaching the average price target will result in a growth of 195.65% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CYAD will report FY 2022 earnings on 03/22/2024. Analysts have provided yearly estimates in a range of -$1.45 being high and -$1.45 being low. For CYAD, this leads to a yearly average estimate of -$1.45. Based on analyst estimates, the high estimate for the next quarter is -$0.91 and the low estimate is -$0.91. The average estimate for the next quarter is thus -$0.91.

Leave a Comment

Your email address will not be published. Required fields are marked *